Hematopoietic/Lymphoid Cancer Clinical Trial
Official title:
A Phase I/II Study of Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB Chimeric Antigen Receptor T-Cells in Patients With Refractory or Recurrent CD19/22+ B-lineage Leukemia/Lymphoma
Clinical study of CD19 CAR-T in the treatment of blood and lymphatic system tumor has been achieved a breakthrough. The main solution in clinical research is to use CD19 CAR-T infusion alone. Because of the heterogeneity of the tumor, the patient often carries tumor cells with CD19 deficient but other positive target antigens (such as CD22). Specifically removal of CD19 positive tumor cells in CAR-T treatment, CD19 negative tumor cells or tumor cells which carry other target antigens would amplify with extra free space released at the same time, resulting in the relapse of tumors of heterogeneities. In order to effectively control the recurrence, CAR-T treatment scheme specific for several target antigens was presented and verified. However treatment with the sequential infusion of different target specific CAR-T cells, the window period between two times infusions may be the opportunity for the tumor recurrence of heterogeneity; and bispecific CAR-T has also been reported only one CAR can be fully functioned. In order to avoid these problems, this topic puts forward for the first time in the international with a treatment scheme of an equal amount of infusion of CD19-41BB and CD22-41BB two Car-T in the treatment of refractory hematologic malignancies. We expect the treatment is more effective in eliminating tumor burden, and also can inhibit the recurrence of tumor heterogeneity at the same time.
To determine:
Primary Outcome Measure:
- Safety (incidence of adverse events defined as dose-limited toxicity)
Secondary Outcome Measures:
- Survival of CAR T cells in circulation measured by flow cytometry and qPCR
- Overall complete remission rate
- Tissue infiltration of transferred CAR-T cells
- In vitro killing potential of infiltrated CAR-T cells
- Phenotype of infused CAR-T cells
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00710632 -
Screening to Predict Weight Loss in Patients With Cancer
|
N/A | |
Active, not recruiting |
NCT01056614 -
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
|
Phase 2 | |
Terminated |
NCT00089089 -
Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT03654404 -
A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients
|
N/A | |
Completed |
NCT01212380 -
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
|
Phase 1 | |
Completed |
NCT00896792 -
Nurse Practitioner Hospice Program for Patients With Terminal Metastatic Cancer and Their Families or Caregivers
|
Early Phase 1 | |
Recruiting |
NCT03110640 -
Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
|
Phase 1 | |
Completed |
NCT01982682 -
Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
|
Phase 2 | |
Completed |
NCT00833898 -
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
|
Phase 3 | |
Active, not recruiting |
NCT05147311 -
Positive Psychology Intervention In HSCT
|
N/A | |
Completed |
NCT04172818 -
Feasibility Study of a Diary for Allogenic Hematopoietic Stem Cell Transplantation Patients and Families
|
N/A | |
Completed |
NCT00670917 -
Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy
|
N/A | |
Withdrawn |
NCT00899808 -
Molecular Markers and Genetic Markers in Patients Undergoing Radiation Therapy for Cancer
|
N/A | |
Recruiting |
NCT02081937 -
CART-19 Immunotherapy in Mantle Cell Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT02194413 -
Effects of Healing Touch on Patients Undergoing Hematopoietic Stem Cell Transplant
|
N/A | |
Completed |
NCT01029366 -
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
|
Phase 1 | |
Terminated |
NCT03121534 -
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
|
Phase 2 | |
Withdrawn |
NCT01620229 -
Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01866969 -
Quality of Life in Caregivers of Hospitalized Older Patients With Cancer
|
N/A | |
Completed |
NCT00068315 -
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 |